Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Dec 1.

Published in final edited form as: Stroke. 2016 Nov 10;47(12):3041–3044. doi: 10.1161/STROKEAHA.116.014418

Table 1.

MRI markers in pre-symptomatic and symptomatic mutation carriers versus controls.

MRI markers	Controls (N=33)		Pre-symptomatic carriers (N=12)		Symptomatic carriers (N=15)
MRI markers	Prevalence	Median (25^th–75^th percentile)	Prevalence	Median (25^th–75^th percentile)	Prevalence	Median (25^th–75^th percentile)
Microbleeds	6.7% (2/30)	0 (0 – 0)	18.2% (2/11)	0 (0 – 0)	100% (15/15)^**	49 (28 – 118)^**
ICHs	0% (0/30)	0 (0 – 0)	9.1% (1/11)	0 (0 – 0)	100% (14/14)^**	13 (5 – 27)^**
Convexity SAHs	0% (0/30)	0 (0 – 0)	18.2% (2/11)	0 (0 – 0)	50% (7/14)^**	0.5 (0 – 2.3)^*
Siderosis (%)	0 % (0/30)	-	9.1% (1/11)	-	93.3% (14/15)^**	-
Cortical microinfarcts (mean, range)	13.8% (4/29)	0.2 (0 – 2)	30.0% (3/10)^*	0.8 (0 – 6)	100% (12/12)^**	5 (2 – 13)^**
WMHs volume (cm³)	-	0.6 (0.2 – 2.2)	-	1.4 (0.4 – 6.0)^**	-	82.4 (50.7 – 133.0)^**
DPVS-CSO	-	3 (2 – 3)	-	3 (2 – 4)	-	4 (3 – 4)^*
DPVS-BG	-	2 (2 – 2)	-	2 (2 – 2)	-	2 (2 – 2)
Lacunar infarcts	32.3% (10/31)	0 (0 – 1)	27.3% (3/11)	0 (0 – 1)	13.3% (2/15)^*	0 (0 – 0)

^*

=p<0.05 and

^**

=p<0.001; controls vs pre-symptomatic carriers and controls vs symptomatic carriers